|
Re: Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
|
6
|
Resverlogix Corp.
|
Jun 14, 2018 03:36PM
|
|
Re: Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
|
6
|
Resverlogix Corp.
|
Aug 28, 2017 08:53AM
|
|
Re: Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
|
1
|
Resverlogix Corp.
|
Aug 28, 2017 09:50AM
|
|
Re: Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
|
1
|
Resverlogix Corp.
|
Dec 19, 2018 09:02AM
|
|
Re: Resverlogix Announces Corporate Update Conference Call...
|
7
|
Resverlogix Corp.
|
Jun 06, 2020 09:15AM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
3
|
Resverlogix Corp.
|
Jun 07, 2020 12:37PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
5
|
Resverlogix Corp.
|
Jun 07, 2020 05:45PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
5
|
Resverlogix Corp.
|
Jun 05, 2020 07:27PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
5
|
Resverlogix Corp.
|
Jun 07, 2020 07:28AM
|
|
Re: Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
|
4
|
Resverlogix Corp.
|
Oct 14, 2020 05:18PM
|
|
Re: Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
|
3
|
Resverlogix Corp.
|
Jan 18, 2022 10:51AM
|
|
Re: Resverlogix Announces Closing of $15 Million Offering
|
2
|
Resverlogix Corp.
|
Jun 07, 2019 08:42AM
|
|
Re: Resverlogix Announces Closing of $15 Million Offering
|
3
|
Resverlogix Corp.
|
Jun 07, 2019 09:55AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
9
|
Resverlogix Corp.
|
Dec 22, 2020 10:19AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 10:31AM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
2
|
Resverlogix Corp.
|
Aug 22, 2019 07:14PM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
|
Resverlogix Corp.
|
Oct 06, 2016 11:23PM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
5
|
Resverlogix Corp.
|
Aug 23, 2019 09:19AM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
2
|
Resverlogix Corp.
|
Oct 07, 2016 08:56AM
|
|
Re: Resverlogix and Zenith Special Meetings
|
2
|
Resverlogix Corp.
|
Jul 01, 2015 11:10AM
|
